Olema Pharmaceuticals, Inc. reports clinical, corporate, and financing developments as a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other cancers. Olema Oncology updates commonly center on palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, and OP-3136, an orally available KAT6 inhibitor.
Recurring company news covers clinical and preclinical presentations at oncology meetings, endocrine-driven cancer biology, ER+/HER2- breast cancer studies, combination approaches with endocrine therapy and CDK inhibitors, operating results, public offerings, inducement equity grants, and board or management changes.
Olema Pharmaceuticals, Inc. announces new clinical data for Palazestrant in combination with Ribociclib to be presented at the 2024 ESMO Breast Cancer Annual Congress. The company will share information from its ongoing Phase 1b/2 clinical study in a poster presentation. The event will take place in Berlin, Germany, on May 15-17, 2024.
Additionally, Olema will host an investor conference call on May 15, 2024, to discuss the data further. The company focuses on developing targeted therapies for women's cancers, marking a significant milestone in its research and development efforts.
Olema Pharmaceuticals, Inc. announced the granting of stock options to new employees under the Company's 2022 Inducement Plan. A total of 187,400 shares of common stock were granted to six employees, with options vesting over four years. The exercise price is set at $10.40 per share, with the options subject to Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) will participate in various investor conferences in May, including the BofA Securities Health Care Conference, H.C. Wainwright BioConnect Investor Conference, UBS Spring Biotech Symposium, and TD Cowen Oncology Innovation Summit. The management team will engage in presentations, fireside chats, and one-on-one meetings to discuss the company's targeted therapies for women's cancers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.